Searched for
GLENMARK PHARMA STOCKS
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...- Capitalmind Flexi Cap Fund adds Nestle India and 10 others, exits SBI and 14 others in MayCapitalmind Flexi Cap Fund made significant portfolio adjustments in May. The fund welcomed Nestle India and eleven new stocks. It also div...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Bank Nifty near key resistance zone; breakout above 54,300 crucial: Ajit MishraIndian equity markets are consolidating within a narrow range, with Nifty struggling to break 24,000 and Bank Nifty showing relative streng...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Ahead of Market: 10 things that will decide stock market action on WednesdayNifty 50 and BSE Sensex declined amid selling in banking, auto and IT stocks. Markets remain range-bound, awaiting triggers, with analysts ...
- Buy the dip, but avoid IT, back pharma & power, says Rudramurthy BVIndian markets are experiencing a healthy correction, according to Vachana Investments' MD, CA Rudramurthy BV. He advises waiting for speci...
- US tariffs on metals and pharma: Which Indian stocks are safe and which aren't: Sudip BandyopadhyayIndian equity markets face policy risks from US tariffs and West Asia conflict. These issues impact metals and pharmaceutical sectors. Expe...
- Tariff threat ain't over yet! Sun Pharma, other pharma stocks plunge up to 6%Pharma stocks fell after reports that the Trump administration may impose tariffs—potentially up to 100%—on drugmakers not ensuring low pri...
- Stock Radar: Glenmark Pharma breaks out from a range to hit fresh record high in March 2026; what should investors do?Glenmark Pharma Ltd has broken out of a 7-month consolidation on weekly charts, reaching fresh record highs. Experts suggest short-term tra...
- Glenmark Pharma shares rally 14% on AbbVie boost; analysts hike targets to Rs 2,800Glenmark Pharma surged 14% after its subsidiary signed a $700 million licensing deal with AbbVie for its experimental cancer drug, ISB 2001...
- Stock Radar: Breakout from falling trendline makes Glenmark an attractive buy; check target & stop lossGlenmark Pharma Ltd has broken out of an 8-month consolidation, breaching a downward trendline. Experts suggest a buy for short-to-medium t...
- Reduce Glenmark Pharmaceuticals, target price Rs 780: ICICI SecuritiesGlenmark Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Other Operating Revenue and Sale of services for the y...
- Buy Glenmark Pharmaceuticals, target price Rs 720: Motilal Oswal Financial ServicesMaking higher lows from the last six months which suggests continuous strength and a fresh breakout.
- Buy Glenmark Pharmaceuticals, target price Rs 440: ICICI DirectGlenmark Pharmaceuticals Ltd., incorporated in the year 1977, is a Mid Cap company (having a market cap of Rs 11089.21 Crore) operating in ...
- Glenmark falls as CS downgrades stock to 'Neutral' ahead of Q1 numbersCredit Suisse believes that the pharma stock is already pricing in the best case scenario, which includes sustenance of profitability from ...
- Buy Glenmark Pharma, stock may touch 390: Ashwani Gujral, Ashwanigujral.comGlenmark Pharma is coming out of a large consolidation. We can stay past 350. Chances are that investors can get closer to levels of about ...
- Pharma stocks will outperform in early phase of market rally: Ashwani Gujral"It seems pharmas will outperform in the early phase of any rally that starts from here and Glenmark, 310 is a key level. "
- Glenmark Pharma may see more downside: Deepak MohoniThe market conditions, in the last week or two, have been quite adverse and that usually has an impact on Glenmark.
- Avoid buying Glenmark Pharma: Deepak Mohoni"If you look at history of Glenmark, it has punished investors on the downside quite a few times."
Load More
